Assessment of Tumor-infiltrating Lymphocytes Using International TILs Working Group (ITWG) System Is a Strong Predictor of Overall Survival in Colorectal Carcinoma A Study of 1034 Patients

被引:78
作者
Fuchs, Talia L. [1 ,2 ,3 ]
Sioson, Loretta [1 ]
Sheen, Amy [1 ]
Jafari-Nejad, Kambin [4 ]
Renaud, Christopher J. [1 ,2 ]
Andrici, Juliana [5 ]
Ahadi, Mahsa [1 ,2 ,3 ]
Chou, Angela [1 ,2 ,3 ]
Gill, Anthony J. [1 ,2 ,3 ]
机构
[1] Royal North Shore Hosp, Kolling Inst Med Res, Canc Diag & Pathol Grp, St Leonards, NSW, Australia
[2] Royal North Shore Hosp, Dept Anat Pathol, NSW Hlth Pathol, Pacific Highway, St Leonards, NSW 2065, Australia
[3] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[4] Douglas Hanly Moir Pathol, Macquarie Pk, NSW, Australia
[5] Univ Bern, Inst Pathol, Bern, Switzerland
关键词
tumor-infiltrating lymphocytes (TILs); colorectal carcinoma (CRC); International TILs Working Group (ITWG); II COLON-CANCER; MICROSATELLITE INSTABILITY; ADJUVANT CHEMOTHERAPY; STANDARDIZED METHOD; SOLID TUMORS; IMMUNOHISTOCHEMISTRY; IDENTIFICATION; PATHOLOGISTS; PROPOSAL;
D O I
10.1097/PAS.0000000000001409
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The presence of increased tumor-infiltrating lymphocytes (TILs) is established as a positive prognostic factor in many malignancies including colorectal carcinoma (CRC). However, multiple different approaches have been used to assess TILs. In 2014, the International TILs Working Group (ITWG) proposed a standardized methodology for evaluating TILs, initially in the context of breast cancer, but subsequently expanded to other malignancies. To date, the efficacy of the ITWG system has not been investigated in a large cohort of all-stage CRC. We, therefore, sought to validate this system in CRC. We used the ITWG system to assess the density of stromal TILs in an unselected cohort of 1034 CRC patients undergoing primary tumor resection at our institution. The percentage TILs' score was categorized into 3 groups: low (0% to 10%), intermediate (15% to 50%), and high (55% to 100%). The mean survival was 53, 67, and 75 months, respectively (P=0.0001). This survival benefit remained statistically significant in multivariate analyses (P=0.0001) and subgroup analyses of mismatch repair-proficient CRCs (P=0.0001), mismatch repair-deficient CRCs (P=0.031), BRAFV600E-mutant CRCs (P=0.0001), and BRAF wild-type CRCs (P=0.001). The predictive value of TILs assessed using the ITWG system was superior to the assessment of intraepithelial lymphocyte performed prospectively using a standard system requiring >= 5 lymphocytes per high-powered field in direct contact with tumor cells or between tumor clusters. We conclude that the ITWG system for assessing TILs is a powerful predictor of all-cause survival in CRC independent of many prognostic factors and superior to the assessment of intraepithelial lymphocytes using a traditional system.
引用
收藏
页码:536 / 544
页数:9
相关论文
共 36 条
  • [1] Histopathological identification of colon cancer with microsatellite instability
    Alexander, J
    Watanabe, T
    Wu, TT
    Rashid, A
    Li, SA
    Hamilton, SR
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (02) : 527 - 535
  • [2] [Anonymous], 2018, ONCOTARGET, DOI [DOI 10.18632/ONCOTARGET.24612, 10.18632/oncotarget.24612]
  • [3] NCCN Guidelines® Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines
    Benson, Al B., III
    Venook, Alan P.
    Al-Hawary, Mahmoud M.
    Cederquist, Lynette
    Chen, Yi-Jen
    Ciombor, Kristen K.
    Cohen, Stacey
    Cooper, Harry S.
    Deming, Dustin
    Engstrom, Paul F.
    Garrido-Laguna, Ignacio
    Grem, Jean L.
    Grothey, Axel
    Hochster, Howard S.
    Hoffe, Sarah
    Hunt, Steven
    Kamel, Ahmed
    Kirilcuk, Natalie
    Krishnamurthi, Smitha
    Messersmith, Wells A.
    Meyerhardt, Jeffrey
    Miller, Eric D.
    Mulcahy, Mary F.
    Murphy, James D.
    Nurkin, Steven
    Saltz, Leonard
    Sharma, Sunil
    Shibata, David
    Skibber, John M.
    Sofocleous, Constantinos T.
    Stoffel, Elena M.
    Stotsky-Himelfarb, Eden
    Willett, Christopher G.
    Wuthrick, Evan
    Gregory, Kristina M.
    Freedman-Cass, Deborah A.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (04): : 359 - 369
  • [4] College of American Pathologist (CAP), 2017, CANC PROT TEMPL PROT
  • [5] Challenges in the Management of Stage II Colon Cancer
    Dotan, Efrat
    Cohen, Steven J.
    [J]. SEMINARS IN ONCOLOGY, 2011, 38 (04) : 511 - 520
  • [6] The Prognostic Value of Tumor-Infiltrating lymphocytes in Stage II Colon Cancer. A Nationwide Population-Based Study
    Eriksen, Ann C.
    Sorensen, Flemming B.
    Lindebjerg, Jan
    Hager, Henrik
    Christensen, Rene dePont
    Kjaer-Frifeldt, Sanne
    Hansen, Torben F.
    [J]. TRANSLATIONAL ONCOLOGY, 2018, 11 (04): : 979 - 987
  • [7] Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
    Galon, Jerom
    Costes, Anne
    Sanchez-Cabo, Fatima
    Kirilovsky, Amos
    Mlecnik, Bernhard
    Lagorce-Pages, Christine
    Tosolini, Marie
    Camus, Matthieu
    Berger, Anne
    Wind, Philippe
    Zinzindohoue, Franck
    Bruneval, Patrick
    Cugnenc, Paul-Henri
    Trajanoski, Zlatko
    Fridman, Wolf-Herman
    Pages, Franck
    [J]. SCIENCE, 2006, 313 (5795) : 1960 - 1964
  • [8] Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.
    Galon, Jerome
    Mlecnik, Bernhard
    Marliot, Florence
    Ou, Fang-Shu
    Bifulco, Carlo Bruno
    Lugli, Alessandro
    Zlobec, Inti
    Rau, Tilman T.
    Hartmann, Arndt
    Masucci, Giuseppe V.
    Zavadova, Eva
    Ohashi, Pam
    Roehrl, Michael H. A.
    Kawakami, Yutaka
    Torigoe, Toshihiko
    Ascierto, Paolo Antonio
    Marincola, Franco
    Sargent, Daniel J.
    Fox, Bernard A.
    Pages, Franck
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer
    Gao, Shanwu
    Tibiche, Chabane
    Zou, Jinfeng
    Zaman, Naif
    Trifiro, Mark
    O'Connor-McCourt, Maureen
    Wang, Edwin
    [J]. JAMA ONCOLOGY, 2016, 2 (01) : 37 - 45
  • [10] Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology
    Giraldo, Nicolas A.
    Peske, J. David
    Sautes-Fridman, Catherine
    Fridman, Wolf H.
    [J]. VIRCHOWS ARCHIV, 2019, 474 (04) : 463 - 474